Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

Abstract Background Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targe...

Celý popis

Podrobná bibliografie

Vydáno v:	Neuro-oncology (Charlottesville, Va.) Ročník 25; číslo 11; s. 2058 - 2071
Hlavní autoři:	Burger, Michael C, Forster, Marie-Therese, Romanski, Annette, Straßheimer, Florian, Macas, Jadranka, Zeiner, Pia S, Steidl, Eike, Herkt, Stefanie, Weber, Katharina J, Schupp, Jonathan, Lun, Jennifer H, Strecker, Maja I, Wlotzka, Karolin, Cakmak, Pinar, Opitz, Corinna, George, Rosemol, Mildenberger, Iris C, Nowakowska, Paulina, Zhang, Congcong, Röder, Jasmin, Müller, Elvira, Ihrig, Kristina, Langen, Karl-Josef, Rieger, Michael A, Herrmann, Eva, Bonig, Halvard, Harter, Patrick N, Reiss, Yvonne, Hattingen, Elke, Rödel, Franz, Plate, Karl H, Tonn, Torsten, Senft, Christian, Steinbach, Joachim P, Wels, Winfried S
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	US Oxford University Press 02.11.2023
Témata:	Glioblastoma - pathology Humans Immunotherapy, Adoptive - methods Killer Cells, Natural Neoplasm Recurrence, Local - drug therapy Receptors, Chimeric Antigen Recurrence human clinical trial NK cells glioblastoma CAR in HER2 phase I first adoptive immunotherapy
ISSN:	1522-8517, 1523-5866, 1523-5866
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!